Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice

References

• PriceDYawnBBrusselleGRossiARisk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrim Care Respir J20132219210023135217
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; updated 2015 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdfAccessed April 28, 2015
   Google Scholar
• O’DonnellDEHernandezPKaplanACanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary careCan Respir J200815Suppl A1A8A
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care; 2010 Available from: https://www.nice.org.uk/guidance/cg101/resources/cg101-chronic-obstructive-pulmonary-disease-update-full-guideline2Accessed April 29, 2015
   Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• MiravitllesMCalleMSoler-CataluñaJJClinical phenotypes of COPD: identification, definition and implications for guidelinesArch Bronconeumol2012483869822196477
   PubMed Web of Science ®Google Scholar
• KankaanrantaHHarjuTKilpelainenMDiagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the Finnish guidelinesBasic Clin Pharmacol Toxicol2015116429130725515181
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
   PubMed Web of Science ®Google Scholar
• KoblizekVPecenLZatloukalJReal-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatmentPLoS One2014911e11107825380287
   PubMed Web of Science ®Google Scholar
• VestboJVogelmeierCSmallMHigginsVUnderstanding the GOLD 2011 strategy as applied to a real-world COPD populationRespir Med2014108572973624675239
   PubMed Web of Science ®Google Scholar
• SuissaSBarnesPJInhaled corticosteroids in COPD: the case againstEur Respir J2009341131619567599
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• YawnBKleerupEZhangJKianifardFWilliamsJInhaled corticosteroid use and GOLD severity stage among patients with chronic obstructive pulmonary disease in different regions [abstract]Am J Respir Crit Care Med2012182A2944
   Web of Science ®Google Scholar
• BabuKSKastelikJAMorjariaJBInhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspectiveBr J Clin Pharmacol201478228230025099256
   PubMed Web of Science ®Google Scholar
• ErnstPSaadNSuissaSInhaled corticosteroids in COPD: the clinical evidenceEur Respir J201545252553725537556
   PubMed Web of Science ®Google Scholar
• HalpinDMGQuintJKThe WISDOM of inhaled corticosteroids in COPDThorax201469121071107225323619
   PubMed Web of Science ®Google Scholar
• VestboJSorensenTLangePBrixATorrePViskumKLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet199935391671819182310359405
   PubMed Web of Science ®Google Scholar
• PauwelsRALofdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary diseaseN Engl J Med1999340251948195310379018
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
   PubMed Web of Science ®Google Scholar
• SinDDTuJVInhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164458058411520719
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPVandemheenKLAaronSDMethodological issues in therapeutic trials of COPDEur Respir J200831592793318216056
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMASeemungalTAHaganGAnsariZStockleyRAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00682922972099
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJBrookRDStudy to understand mortality and morbidity in COPD (SUMMIT) [abstract]Eur Respir J201546Suppl 59OA3476
   Google Scholar
• CrimCCalverleyPMAAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J200934364164719443528
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• YangIAClarkeMSSimEHFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00299122786484
   PubMed Web of Science ®Google Scholar
• KimJHParkJSKimKHJeongHCKimEKLeeJHInhaled corticosteroid is associated with an increased risk of TB in patients with COPDChest201314341018102423079688
   PubMed Web of Science ®Google Scholar
• BrassardPSuissaSKezouhAErnstPInhaled corticosteroids and risk of tuberculosis in patients with respiratory diseasesAm J Respir Crit Care Med2011183567567820889902
   PubMed Web of Science ®Google Scholar
• CummingRGMitchellPLeederSRUse of inhaled corticosteroids and the risk of cataractsN Engl J Med199733718149203425
   PubMed Web of Science ®Google Scholar
• ErnstPLow-dose inhaled and nasal corticosteroid use and the risk of cataractsEur Respir J20062761168117416481387
   PubMed Web of Science ®Google Scholar
• LokeYKCavallazziRSinghSRisk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studiesThorax201166869970821602540
   PubMed Web of Science ®Google Scholar
• SuissaSKezouhAErnstPInhaled corticosteroids and the risks of diabetes onset and progressionAm J Med2010123111001100620870201
   PubMed Web of Science ®Google Scholar
• HayCMSprattDIAdrenal insufficiency in a woman secondary to standard-dose inhaled fluticasone propionate therapyEndocrinol Diabetes Metab Case Rep2014201413008024683484
   PubMedGoogle Scholar
• CalverleyPMWhat to use INSTEAD of inhaled corticosteroids in COPD?Eur Respir J20144461391139325435522
   PubMed Web of Science ®Google Scholar
• SuissaSCoulombeJErnstPDiscontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumoniaChest Epub2015625
   Google Scholar
• JaradNAWedzichaJABurgePSCalverleyPMAn observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study GroupRespir Med199993316116610464871
   PubMed Web of Science ®Google Scholar
• O’BrienARusso-MagnoPKarkiAEffects of withdrawal of inhaled steroids in men with severe irreversible airflow obstructionAm J Respir Crit Care Med2001164336537111500334
   PubMed Web of Science ®Google Scholar
• SchermerTRHendriksAJChavannesNHProbability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practicePrim Care Respir J2004131485516701637
   PubMedGoogle Scholar
• van der ValkPMonninkhofEvan der PalenJZielhuisGvan HerwaardenCEffect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med2002166101358136312406823
   PubMed Web of Science ®Google Scholar
• WoutersEFMWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
   PubMed Web of Science ®Google Scholar
• ChoudhuryABDawsonCMKilvingtonHEWithdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trialRespir Res200789318162137
   PubMed Web of Science ®Google Scholar
• NadeemNJTaylorSJCEldridgeSMWithdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodologyRespir Res20111210721838890
   PubMed Web of Science ®Google Scholar
• MagnussenHWatzHKirstenAStepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationaleRespir Med2014108459359924477080
   PubMed Web of Science ®Google Scholar
• RossiAGuerrieroMCorradoAOPTIMO/AIPO Study GroupWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTOlmoRdINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J20144461548155625359348
   PubMed Web of Science ®Google Scholar
• LeuppiJDSalomeCMJenkinsCRPredictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroidsAm J Respir Crit Care Med2001163240641211179114
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• MagnussenHTetzlaffKCalverleyPMInhaled glucocorticoids and COPD exacerbationsN Engl J Med20153721939425551535
   PubMedGoogle Scholar
• Alcazar NavarreteBCasanovaCMiravitllesM“Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease”: a consensus documentArch Bronconeumol201551419319825540900
   PubMed Web of Science ®Google Scholar
• BramanSSThe chronic obstructive pulmonary disease-asthma overlap syndromeAllergy Asthma Proc2015361111825562551
   PubMed Web of Science ®Google Scholar
• BujarskiSParulekarADSharafkhanehAHananiaNAThe Asthma COPD Overlap Syndrome (ACOS)Curr Allergy Asthma Rep201515319
   Web of Science ®Google Scholar
• LouieSZekiAASchivoMThe asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerationsExpert Rev Clin Pharmacol20136219721923473596
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA)Global Initiative for Chronic Obstructive Lung Disease (GOLD)Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS); 2015 Available from: http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdfAccessed May 4, 2015
   Google Scholar
• GershonASCampitelliMACroxfordRCombination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary diseaseJAMA2014312111114112125226477
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• AgustiAFabbriLInhaled steroids in COPD: when should they be used?Lancet Respir Med201421186987125439566
   PubMed Web of Science ®Google Scholar
• BeehKMDeromEEchave-SustaetaJENERGITO: efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol [abstract]Eur Respir J201546Suppl 59PA4366
   Google Scholar
• BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
   PubMed Web of Science ®Google Scholar
• LieskerJJBathoornEPostmaDSVonkJMTimensWKerstjensHASputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPDRespir Med2011105121853186021802933
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• SivaRGreenRHBrightlingCEEosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trialEur Respir J200729590691317301099
   PubMed Web of Science ®Google Scholar
• WedzichaJAPriceDMezziKFogelRBanerjiDQVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: a pooled analysis of LANTERN and ILLUMINATE [abstract]Eur Respir J201546Suppl 59PA1005
   Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• Vedel-KroghSNielsenSFLangePVestboJNordestgardBGBlood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen General Population Study [abstract]Eur Respir J201546Suppl 59OA2934
   Google Scholar
• AntusBBartaIHorvathICsiszerERelationship between exhaled nitric oxide and treatment response in COPD patients with exacerbationsRespirology201015347247720210889
   PubMed Web of Science ®Google Scholar
• SoterSBartaIAntusBPredicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxideInflammation20133651178118523681903
   PubMed Web of Science ®Google Scholar
• BjermerLAlvingKDiamantZCurrent evidence and future research needs for FeNO measurement in respiratory diseasesRespir Med2014108683084124636813
   PubMed Web of Science ®Google Scholar
• DweikRABoggsPBErzurumSCAn official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applicationsAm J Respir Crit Care Med2011184560261521885636
   PubMed Web of Science ®Google Scholar
• BarnesPJInhaled corticosteroidsPharmaceuticals201033514540
   Google Scholar
• Lung Health Study Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260
   PubMed Web of Science ®Google Scholar
• AlsaeediASinDDMcAlisterFAThe effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trialsAm J Med20021131596512106623
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and toler-ability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar